Lonza | LONN - Cash And Equivalent



Lonza reported CHF1.11B in Cash and Equivalent for its fiscal semester ending in December of 2024.


Cash And Equivalent Change Date
Akzo Nobel EUR 1.55B 47M Jun/2025
Alcon AG USD 1.41B 4M Jun/2025
Almirall EUR 374.4M 2.7M Mar/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
BASF EUR 2.52B 203M Jun/2025
Bayer EUR 4.56B 542M Jun/2025
Beiersdorf EUR 1.17B 40M Jun/2025
Covestro EUR 489M 253M Jun/2025
Demant 1.14B 30M Jun/2025
Fresenius EUR 1.23B 1.16B Jun/2025
Fresenius Medical Care EUR 1.72B 644.08M Jun/2025
Geberit CHF 403.6M 4.1M Mar/2025
Genmab DKK 1.3B 323M Jun/2025
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.6B 865M Jun/2025
GN Store Nord DKK 787M 99M Mar/2025
Hikma Pharmaceutical USD 188M 188M Dec/2024
Johnson Matthey GBP 898M 277M Mar/2025
Merck EUR 1.17B 161M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Philips EUR 1.82B 629M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sanofi 15.36B 7.37B Jun/2025
Sika AG CHF 707.5M 59.3M Dec/2024
Solvay EUR 333M 118M Jun/2025
UCB EUR 1.57B 1.14B Dec/2024